Cerebras
CBRS
$214.00
-5.54%
Cerebras Systems Inc. is an AI infrastructure company that designs and builds the world's largest semiconductor chips and integrated systems for high-performance AI training and inference. The company positions itself as a disruptive force in the semiconductor industry, challenging incumbents with its unique wafer-scale engine architecture to power industry-leading supercomputers for complex AI workloads. The current investor narrative is dominated by its recent, highly volatile public debut, with the stock surging 68% on its first trading day, which has framed it as a bellwether for investor appetite in high-growth, pre-profitability AI tech ahead of other major IPOs like SpaceX.…
CBRS
Cerebras
$214.00
Related headlines
Investment Opinion: Should I buy CBRS Today?
Rating: Hold. The core thesis is that while Cerebras possesses disruptive technology in a secular growth market, its current valuation is unjustifiable and its operational profile is too weak to recommend purchase, but the sharp post-IPO correction warrants monitoring rather than outright sale.
Supporting this view, the stock trades at a nonsensical 131.3x trailing sales and a negative forward PE, indicating it is priced for decades of flawless execution. While the EV/Sales of 25.1x is more palatable, it remains a premium for a company with a -28.5% operating margin. The 30.8% decline from its IPO close shows the market is already repricing this extreme optimism, but it remains far from a fundamental floor. The lack of analyst targets removes a key valuation anchor, increasing uncertainty.
The thesis would upgrade to a speculative Buy only if the stock falls significantly further (e.g., below $180) to provide a larger margin of safety for the high risk, or if the first few public quarters demonstrate accelerating revenue growth and a credible path to operating margin improvement. It would downgrade to Sell if revenue growth stalls or operating losses widen, confirming the valuation is entirely disconnected from reality. Relative to its own brief history and the financial fundamentals, the stock is profoundly overvalued.
Sign up to view all
CBRS 12-Month Price Forecast
The assessment is neutral with medium confidence, reflecting a standoff between a compelling long-term narrative and untenable short-term fundamentals. The key is time: the company needs several quarters to prove its model, but the valuation affords no room for error. The stance would upgrade to bullish only upon evidence of revenue scaling that begins to rationalize the sales multiple, coupled with a material reduction in operating losses. It would turn bearish if the upcoming earnings reports confirm the fears of a 'story stock' without substance, likely triggering a rapid descent towards the bear case target range.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Cerebras's 12-month outlook, with a consensus price target around $278.20 and implied upside of +30.0% versus the current price.
Average Target
$278.20
7 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
7
covering this stock
Price Range
$171 - $278
Analyst target range
Insufficient analyst coverage is available for Cerebras Systems, as the 'recommendation' field is listed as 'none' and no institutional ratings or target prices are provided in the dataset. This is typical for a company that has been public for less than a month, as sell-side analysts often observe a quiet period post-IPO before initiating formal coverage. The lack of coverage implies higher volatility and less efficient price discovery, as the stock is primarily driven by retail sentiment, media narratives, and institutional flows without the anchoring effect of consensus estimates. The provided news snippets highlight the polarized debate, ranging from views of it being a promising AI challenger to warnings about its sky-high valuation and unproven model, which aligns with the high uncertainty and wide dispersion of opinions one would expect before formal analyst research is published.
Bulls vs Bears: CBRS Investment Factors
The evidence currently leans bearish, dominated by an indefensible valuation, operational losses, and severe post-IPO price deterioration. The bull case rests almost entirely on the long-term potential of its disruptive technology, but this is a binary, high-risk bet. The single most important tension in the investment debate is between Cerebras's revolutionary technological promise and its current financial reality of burning cash at a valuation requiring perfection. The resolution of this tension—specifically, whether the company can translate its architectural advantage into rapid, profitable revenue scaling before investor patience or capital runs out—will determine the ultimate success or failure of the investment.
Bullish
- Disruptive AI Infrastructure Technology: Cerebras's wafer-scale engine architecture is a unique, potentially paradigm-shifting approach to AI compute, challenging incumbents like Nvidia. The company's narrative as a high-growth AI disruptor fueled a 68% first-day IPO surge, indicating strong initial investor belief in its long-term potential.
- Strong Short-Term Liquidity Position: The company's current ratio of 2.15 indicates robust short-term liquidity, providing a financial buffer to fund its capital-intensive growth and R&D efforts. This is a critical positive for a pre-profitability firm navigating the volatile early stages of public life.
- Significant Post-IPO Price Correction: The stock has corrected sharply, down 30.8% from its first-day close and trading near its 52-week low of $205.47. This repricing from extreme IPO euphoria levels reduces some of the initial speculative froth and may present a more attractive entry point for high-conviction, long-term investors.
- EV/Sales Multiple More Reasonable than P/S: While the trailing P/S ratio is astronomical at 131.3x, the EV-to-Sales ratio of 25.1x, while still premium, is materially lower. This suggests the market cap incorporates a significant cash balance, making the enterprise value-based valuation less extreme than the headline equity multiple implies.
Bearish
- Astronomical Valuation with No Earnings: The trailing Price-to-Sales ratio of 131.3x is unsustainable by any standard, pricing in decades of flawless, hyper-growth. With a negative forward PE of -2.44 and negative ROE/ROA, the company is valued on narrative alone, leaving it highly vulnerable to multiple compression.
- Severe Operating Losses and Cash Burn: The company's operating margin is deeply negative at -28.5%, and the extreme Price-to-Cash Flow ratio of -6,661.8 strongly implies significant cash burn. This operational unprofitability is a major risk, as it necessitates continued capital raises or reliance on cash reserves to fund growth.
- Extreme Volatility and Technical Downtrend: The stock is in a severe downtrend, falling 29.1% in just over two weeks, starkly underperforming the S&P 500's 4.6% gain. With a max drawdown of -31.44% and high volume, it exhibits the speculative, high-risk trading behavior of a newly public company with no earnings anchor.
- Zero Analyst Coverage and Unproven Model: The complete lack of sell-side analyst coverage ('recommendation: none') means price discovery is inefficient and driven by sentiment. News headlines highlight the unproven business model, and the company's success is purely prospective, increasing uncertainty and investment risk.
CBRS Technical Analysis
The stock is in a pronounced and volatile downtrend following its explosive IPO, with the current price of $215.40 representing a decline of approximately 30.8% from its first-day close of $311.07. Trading at roughly 55.7% of its 52-week range ($205.47 to $386.34), the stock is positioned in the lower half, suggesting the post-IPO euphoria has dissipated, presenting a potential value opportunity but also significant risk as it tests its recent lows. Recent momentum is decisively negative, with the price dropping from $303.63 on May 19 to $215.40 on June 4, a 29.1% decline in just over two weeks, which starkly diverges from the broader market's positive performance as indicated by the S&P 500's 4.6% 1-month gain. This severe short-term underperformance signals intense selling pressure and a rapid repricing from its IPO highs, likely driven by profit-taking and valuation concerns. Key technical levels are clear, with immediate support at the 52-week low of $205.47 and major resistance at the 52-week high of $386.34; a breakdown below $205.47 would signal a failure of the IPO price support and potentially trigger further declines, while a recovery above the $300 level is needed to suggest the sell-off has stabilized. The stock exhibits extreme volatility, underscored by a max drawdown of -31.44% within the provided data period and an average daily volume of over 4.1 million shares, indicating high-risk, speculative trading activity typical of a newly public company.
Beta
—
—
Max Drawdown
-35.4%
Largest decline past year
52-Week Range
$197-$386
Price range past year
Annual Return
—
Cumulative gain past year
| Period | CBRS Return | S&P 500 |
|---|---|---|
| 1m | — | -0.1% |
| 3m | — | +12.0% |
| 6m | — | +8.8% |
| 1y | — | +22.9% |
| ytd | — | +8.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CBRS Fundamental Analysis
Revenue and growth trajectory analysis is severely limited as quarterly financials and income statement data are not available in the provided dataset, preventing a detailed assessment of sales trends, YoY growth rates, or segment performance. The company's profitability profile is mixed, with a positive but minuscule trailing EPS of $0.0036 and a net margin of 0.47%, yet it reports negative Return on Equity (-0.411) and Return on Assets (-0.053), indicating it is not generating economic profit on its capital base. Operating and gross margins provide further insight, with a gross margin of 39.0% but a deeply negative operating margin of -28.5%, highlighting significant operating expenses that are currently overwhelming gross profit. Balance sheet and cash flow health are ambiguous; the company shows a strong current ratio of 2.15, suggesting good short-term liquidity, but a negative debt-to-equity ratio of -0.45, which is an unusual figure often resulting from an accounting treatment of equity (potentially due to accumulated deficits). Critical cash flow metrics like Free Cash Flow are unavailable, and the Price-to-Cash Flow ratio is an extreme -6,661.8, which, while not directly interpretable as a yield, strongly implies the company is burning cash, a common characteristic for an early-stage, capital-intensive semiconductor firm investing heavily in growth.
Quarterly Revenue
N/A
N/A
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
N/A
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CBRS Overvalued?
Given the company's minimal positive net income (EPS of $0.0036), the primary valuation metric selected is the Price-to-Sales (PS) ratio, as profitability is not yet meaningful or sustainable. The trailing PS ratio is an exceptionally high 131.3x, which reflects the market's extreme growth expectations for this pre-profitability AI disruptor. A forward PE ratio is also provided but is negative at -2.44, further confirming that earnings-based valuation is not applicable at this stage. Peer comparison is challenging due to a lack of provided industry average multiples; however, a PS ratio of 131.3x is astronomically high by any standard, indicating the stock is priced for perfection and future revenue growth that must materialize at an extraordinary pace to justify this valuation. The EV-to-Sales ratio of 25.1x, while still premium, is materially lower than the PS ratio, suggesting the market capitalization incorporates a significant cash balance or other adjustments not captured in the equity value. Historical context is unavailable as the company just completed its IPO on May 14, 2026, so there is no meaningful historical trading range for its valuation multiples; the current multiples represent the initial market pricing of its growth narrative, which has already undergone significant compression from its first-day trading highs.
PE
281.5x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-600.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are severe. The company operates at a significant loss, with an operating margin of -28.5% and implied heavy cash burn, as suggested by the extreme Price-to-Cash Flow ratio of -6,661.8. With negative ROE (-0.411) and ROA (-0.053), it destroys shareholder capital on its current base. The valuation is entirely dependent on future revenue growth materializing at an extraordinary pace to justify a P/S of 131.3x, creating immense execution risk. Any slowdown in top-line expansion would trigger a catastrophic derating.
Market & Competitive Risks are pronounced. The stock trades at a stratospheric premium with no earnings, making it acutely sensitive to shifts in risk appetite and growth stock multiples. Its performance is already decoupled from the market, falling 29% while the S&P rose 4.6% over a similar period. As a direct challenger to entrenched giants like Nvidia, it faces formidable competitive and execution hurdles. Furthermore, its fate is tied to the broader AI IPO narrative, with news highlighting its role as a bellwether for SpaceX's upcoming debut, introducing macro-sentiment risk beyond its control.
Worst-Case Scenario involves a failure to meet the hyper-growth expectations embedded in its price, leading to a rapid loss of investor confidence. A chain of disappointing initial quarterly reports post-IPO, coupled with a broader cooling in AI enthusiasm, could trigger a vicious cycle of selling. The realistic downside is a return to and breach of the 52-week low of $205.47, with potential for a further 30-40% decline from current levels as the narrative completely unwinds. From the current price of $215.40, an investor could face a loss of 20-25% to the immediate support level, with catastrophic losses exceeding 50% in a full bear case where the growth story is questioned.
FAQ
The key risks are: 1) Valuation & Execution Risk: The extreme P/S multiple of 131.3x requires flawless execution; any growth stumble will cause a massive price decline. 2) Financial Risk: The company is burning cash (implied by P/CF of -6,661.8) and operates at a -28.5% margin, risking future dilution or liquidity issues. 3) Competitive & Market Risk: It challenges giants like Nvidia in a capital-intensive sector and is highly sensitive to shifts in AI stock sentiment, as shown by its 29% drop while the market rose. 4) Information Risk: Lack of analyst coverage and limited financial history post-IPO make informed analysis difficult, increasing volatility.
Given the high uncertainty, a probabilistic forecast is more appropriate. The base case (50% probability) sees the stock trading between $190 and $240 over the next 12 months as volatility persists while investors await proof of execution. The bull case (20% probability) targets $300-$350, contingent on blowout quarterly earnings that validate the growth narrative. The bear case (30% probability) forecasts a drop to $150-$190 if initial results disappoint, breaking key technical support. The base case is most likely, assuming the company shows decent growth but fails to justify its extreme initial valuation, leading to a gradual grind lower or sideways action.
CBRS is profoundly overvalued based on any conventional financial metric. A trailing Price-to-Sales ratio of 131.3x implies the market expects revenue to grow at an extraordinary and sustained pace for many years. The negative forward PE (-2.44) and operating margin (-28.5%) confirm earnings-based valuation is irrelevant. While the EV/Sales of 25.1x is lower, it remains a significant premium. The valuation is not grounded in current fundamentals but in future potential, meaning the stock is priced for perfection and is highly vulnerable to any disappointment.
CBRS is not a good stock to buy for the vast majority of investors. It is a highly speculative investment with an astronomical valuation (P/S of 131.3x), no current profitability, and extreme volatility, having fallen 30.8% from its IPO close. It could be considered only by investors with a very high risk tolerance, a long-term horizon (5+ years), and a firm belief in its technology who are willing to accept a high probability of permanent capital loss. For such investors, any purchase should be small, phased, and made with the understanding that it is a binary bet on an unproven business model.
CBRS is unsuitable for short-term trading for all but the most sophisticated and risk-aware traders due to its extreme volatility and lack of catalysts. It is theoretically a long-term investment, but only for investors with a 5-7 year horizon who are betting on the technology's ultimate success. However, the 'long-term' suitability is severely questioned by the current valuation, which already discounts decades of success. A more pragmatic approach is to consider it a monitoring position; investors should watch from the sidelines for several quarters to assess execution before committing capital, implying an effective minimum holding period of 'indefinite, pending data.'